|
Status |
Public on Dec 19, 2020 |
Title |
Single cell RNA sequencing analysis of freshly resected PC9 cell line-derived tumor xenografts |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. Using PC9 cells, we generated EGFR-mutant lung cancer xenografts to study the differences in response between individual cells and cell populations. We performed treatment of PC9 xenograft tumors with the combination of osimertinib and crizotinib as well as single drugs, followed by Drop-seq. The addition of crizotinib was guided by our previous data in PC9 grown in cell culture that identified an erlotinib-resistant drug population sensitive to crizotinib. The results of the xenograft study show that combination treatment targets specific osimertinib-tolerant cell populations but leaves a subset of the population that is tolerant to the combo. Each cell subpopulation is characterized by specific molecular signatures. The results of our study help to address emerging drug resistance that limits clinical usefulness of targeted strategies, particularly in NSCLC.
|
|
|
Overall design |
examining drug resistant cell populations using single cell RNA-seq
|
|
|
Contributor(s) |
Benevolenskaya EV, Aissa AF, Islam AB |
Citation(s) |
33712615 |
|
Submission date |
Oct 27, 2020 |
Last update date |
Mar 22, 2021 |
Contact name |
Elizaveta V Benevolenskaya |
E-mail(s) |
[email protected]
|
Phone |
312-413-8947
|
Organization name |
University of Illinois at Chicago
|
Department |
Biochemistry and Molecular Genetics
|
Street address |
900 S. Ashland Ave.
|
City |
Chicago |
State/province |
IL |
ZIP/Postal code |
60607 |
Country |
USA |
|
|
Platforms (1) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (4)
|
|
This SubSeries is part of SuperSeries: |
GSE149383 |
Drug resistant changes at the level of single cells |
|
Relations |
BioProject |
PRJNA672709 |
SRA |
SRP289568 |